Drug Repurposing of Itraconazole and Estradiol Benzoate against COVID‐19 by Blocking SARS‐CoV‐2 Spike Protein‐Mediated Membrane Fusion
Chan Yang, Wei Xü(Southern Medical University), Yan Wu(Chinese Academy of Sciences), Gengfu Xiao(Chinese Academy of Sciences), Yuan Huang(Cleveland Clinic), Xiaoyan Pan(Guizhou University), Yihong Wan(Shenzhen Bay Laboratory), Shuwen Liu(Zhengzhou University), Rong Zhang(Huazhong Agricultural University), Zhaofeng Li(Jiangnan University), Chen Cheng(Institute of Mining), Weijuan Shang(Chinese Academy of Sciences), Yunxia Xu(Guangzhou Eighth People's Hospital), Xinfeng Xu(Southern Medical University), Xiaoge Niu(Southern Medical University)
Cited by 36
Related Papers
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|Cell Research|2020|1.4k
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
|Cellular and Molecular Immunology|2020|759
Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2
|Cell|2022|538
Mxra8 is a receptor for multiple arthritogenic alphaviruses
|Nature|2018|455